CD274 and non-small cell lung carcinoma: In the CheckMate 227 trial, it was observed that in patients with NSCLC who had PD-L1 expression levels equal to or greater than 1%, the combination of nivolumab plus ipilimumab resulted in longer OS compared to traditional platinum-based therapy.